


RESEARCH

Open Access



Tetraspanins are unevenly distributed across single extracellular vesicles and bias sensitivity to multiplexed cancer biomarkers

Rachel R. Mizenko¹, Terza Brostoff², Tatu Rojalin¹, Hanna J. Koster¹, Hila S. Swindell³, Gary S. Leiserowitz⁴, Aijun Wang^{1,3} and Randy P. Carney^{1*} 

Abstract

Background: Tetraspanin expression of extracellular vesicles (EVs) is often used as a surrogate for their detection and classification, a practice that typically assumes their consistent expression across EV sources.

Results: Here we demonstrate that there are distinct patterns in colocalization of tetraspanin expression of EVs enriched from a variety of in vitro and in vivo sources. We report an optimized method for the use of single particle antibody-capture and fluorescence detection to identify subpopulations according to tetraspanin expression and compare our findings with nanoscale flow cytometry. We found that tetraspanin profile is consistent from a given EV source regardless of isolation method, but that tetraspanin profiles are distinct across various sources. Tetraspanin profiles measured by flow cytometry do not totally agree, suggesting that limitations in subpopulation detection significantly impact apparent protein expression. We further analyzed tetraspanin expression of single EVs captured non-specifically, revealing that tetraspanin capture can bias the apparent multiplexed tetraspanin profile. Finally, we demonstrate that this bias can have significant impact on diagnostic sensitivity for tumor-associated EV surface markers.

Conclusion: Our findings may reveal key insights into protein expression heterogeneity of EVs that better inform EV capture and detection platforms for diagnostic or other downstream use.

Keywords: Exosomes, Single-particle characterization, ExoView, Ovarian cancer, Placental mesenchymal stem cells

Introduction

The promise of extracellular vesicles (EVs) for unbiased diagnostic and therapeutic application requires identification of ubiquitous markers that can distinguish EVs from the contaminating background of free protein aggregates, microparticles, lipoprotein, and numerous other nanoparticulate assemblies found in human biofluids. The group of tetraspanins CD9, CD63, and CD81 are the most common EV-associated markers reported in the

literature and have been used for “total” EV capture in many studies, including ELISA [1, 2], flow cytometry [3, 4], and lab-on-a-chip assays [5, 6]. Each of these tetraspanins has been demonstrated to play an active role in EV biogenesis or cargo sorting, suggesting their essential role in the EV secretory pathway [7–9]. While initial work suggested the universal enrichment of these membrane proteins in EVs isolated across cell types [10, 11], recent studies show they are in fact heterogeneously expressed across EVs [12–14]. Such variance in expression suggests the existence of distinct EV subpopulations with significant functional differences. Using this panel of tetraspanins as general “EV-specific” biomarkers may erroneously bias results. To our knowledge, no group has studied the

*Correspondence: rcarney@ucdavis.edu

¹ Department of Biomedical Engineering, University of California, Davis, USA

Full list of author information is available at the end of the article



© The Author(s) 2021. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

frequency and colocalization patterns of tetraspanins on single EVs across sources and isolation methods, a crucial step in understanding their role as generic EV biomarkers and their colocalization with clinically relevant markers.

There is a lack of techniques that can assess multiplexed expression of membrane proteins at single vesicle resolution across the size range of EVs, with the majority of EVs being between ~30 and 100 nm in diameter [15]. Negative staining transmission electron microscopy (TEM) and cryo-EM provide indirect imaging of protein expression via antibody-bound metal nanoparticle probes, thus are close to ground truth [11, 16–18]. Yet, it remains technically demanding to produce high quality EM data, and artefacts in sample preparation and imaging projection can affect interpretation. Furthermore, multiplexing is limited to only a few markers at a time, since distinct sizes of metallic probes are needed [16]. Bead-based flow cytometry permits multiplexed protein expression analysis of EVs, but relies on bulk analysis of at least thousands of EVs, and is biased according to choice of bead-bound biorecognition element [4, 19]. Commercial flow cytometers can assay protein expression at single EV resolution [20, 21] but only above a critical nominal size of ~80 nm, since detection is limited by particle scattering, thus is dependent on particle diameter, particle refractive index, the angle of collection, and the intensity and wavelength of the laser [20]. Some studies have reduced this size limit by detecting particles using fluorescence instead of scattering, yet are still limited in sensitivity to EVs that highly express a single protein [22].

Single particle interferometric reflectance imaging sensing (SP-IRIS) combined with antibody-based microchip capture and fluorescence detection represents an emerging technique that can identify single vesicles with a lower size limit of detection compared to scattering based techniques [23]. SP-IRIS has a theoretical detection limit down to single molecule size, but is more practically ~50 nm for routine measurement [24]. In addition to breaching the diffraction limit, this technique can identify multiplexed expression of membrane proteins on single EVs when paired with fluorescence microscopy and an antibody-fluorophore sandwich assay. A commercial SP-IRIS platform, the ExoView R100 (NanoView Biosciences), utilizes a microarray chip for antibody capture against the tetraspanins CD9, CD63, and CD81 (custom arrays are also available).

In this study, we apply the ExoView platform to examine tetraspanin profiles of single EVs from a variety of sources, including cancer cells, stem cells, and human serum, isolated by either ultracentrifugation (UC) or size exclusion chromatography (SEC). We report that tetraspanins are not homogeneously multiplexed across all EVs, but that consistent multiplexed subpopulations are


present in a given EV isolate. We explore the impact of heterogeneous tetraspanin colocalization as a form of bias that may impact sensitivity to specific disease markers, especially for platforms where CD9, CD63, or CD81 capture is the common first step to enrich EVs for downstream biomarking. To examine this, we developed a custom assay on the ExoView platform utilizing non-specific biotin-based EV capture to examine the bias of direct tetraspanin capture in selecting specific subpopulations. This work describes the first comparison of single-EV protein expression by immunofluorescence across a variety of EV sources and isolation techniques and could be applied to identify a variety of protein expression subpopulations of interest for diagnostics or therapeutics application.

Results

EV generation, isolation, and characterization

We first investigated the consistency of EV tetraspanin expression across biofluid source and isolation method. As sources, we chose isolated EVs from PMSCs, due to their known therapeutic applications, as well as ovarian cancer (OvCa) cells and serum from OvCa human patients, due to their utility for clinical diagnostics. For isolation methodology, we chose either ultracentrifugation (UC), as previously described [25], or size exclusion chromatography (SEC) since these are common isolation methods used by EV researchers [26]. UC and SEC are known to enrich small EVs, which contains the canonical exosomes, a subclass of EVs defined by their biogenesis via inward budding into multivesicular bodies (MVBs) and subsequent release to extracellular space. However, since other types of EVs, such as microvesicles, ectosomes, exomeres, etc., have overlapping size and density, and there are no known exosome-exclusive markers or features, it is not currently possible to ensure that all isolated EVs originate from the MVBs. Therefore, in this work, we more generally apply the term “EVs” to encompass the diverse array of particles isolated by either UC or SEC.

EVs produced from SK-OV-3 cells, a human OvCa cell-line, were utilized to first optimize our incubation procedure for immunocapture. SK-OV-3 cells were grown in a bioreactor, which allows for continuous collection of EVs at high concentrations [27, 28]. EVs were isolated from the conditioned media in the cell compartment each week [27] and extensively characterized to confirm the presence of EVs. TEM images revealed particles of varying size with a deflated cup shape, an artefactual morphology characteristic of EVs when imaged by TEM (Fig. 1a) [29, 30]. In accordance with the *Minimum Information for Studies of Extracellular Vesicles 2018* (MISEV2018) guidelines [10], the presence of



proteins was confirmed by Western blot for CD9, CD63, and CD81 (Fig. 1b), and NTA confirmed that EVs were isolated at a high concentration with a peak diameter of 128.8 nm (Fig. 1c).


We compared the apparent size distributions of SK-OV-3 EVs between NTA, TEM, and SP-IRIS. TEM (Fig. 1a, d, with additional micrographs in Additional file 1: Figure S1) is the closest to ground truth, with a mode diameter of ~35 nm and 50% of total EVs by count in the size range from 40 to 90 nm. NTA exhibits known artefacts in measuring EV size, given that it is only capable of detecting EVs larger than ~70 nm in nominal diameter due to the low scattering of organic particles [15]. This results in an apparent mode between 100 and 150 nm (Fig. 1c), not in agreement with TEM measurement, which shows a log-linear particle count vs. size down to ~30 nm (Fig. 1d) [15]. SP-IRIS size distributions of CD81-captured EVs showed a mode diameter of 50 nm (representative size data for anti-CD81 capture is shown) and a size profile more similar to TEM than NTA, i.e., a logarithmic-linear decrease below 100 nm (Fig. 1e). Similar size profiles were obtained for CD9 and CD63 capture.

Optimizing incubation concentration to identify single-EVs

In SP-IRIS, EVs are incubated on a microarray of antibody spots against CD9, CD63, CD81, or mouse immunoglobulin G (MIgG, a non-specific binding control). Captured particles can be measured in two ways: (1) count and multiplexed marker expression by immunofluorescence (Fig. 2a), or (2) count and size by interferometry (SP-IRIS, Fig. 2b). For fluorescence detection, the ExoView R100 permits detection of up to three color channels following immunocapture. Fluorescence is captured following excitation by LED and images are superimposed to identify co-expression of each protein on a single EV (Fig. 2c).

SP-IRIS mode uses the interference of two reflected light paths illuminated by LED, one that passes through a bound particle and another through an empty part of the thin film silicon chip (Fig. 2b) [23, 24]. The resulting interference pattern provides increased resolution beyond the diffraction limit, and in principle does not have a particle size limitation [24]. Due to potential issues with sample drift over long integration times required for single particle imaging, the ExoView platform currently features a practical detection limit down to ~50 nm, assuming a constant refractive index of 1.4 (Fig. 2d).

Although some reports of EV analysis using the new ExoView platform are beginning to emerge [24], to our knowledge, there is no reporting of optimization for reliable detection of single particles. Therefore, prior to analyzing the tetraspanin profile of EVs, we identified the optimal concentration of SK-OV-3 EVs that maximized EV count while ensuring that each identified particle was a single EV. Using a standard tetraspanin microarray featuring four repeated spots each of anti-CD63, anti-CD9, anti-CD81, and anti-MIgG, we performed a serial dilution on SK-OV-3 EVs, ranging from bulk concentration of 4×10^7 to 4×10^9 particles mL^{-1} (as measured by NTA). First the number of EVs detected by each method was compared to identify the sensitivity of each method. Number of EVs identified by fluorescence was determined by adding all particles with higher fluorescent intensity than the MIgG spot in one or more channels. In interferometry-based SP-IRIS mode, approximately $10 \times$ fewer EVs were detected compared to fluorescent detection (Fig. 2e). Although error bars are difficult to see in this figure, the standard deviation of the three capture spots per chip is included; however, it was much smaller than the differences in number of EV captured at different incubation concentrations. As the largest number of SK-OV-3 EVs were identified by anti-CD81 capture/CD81 detection for this sample, this combination was used for this analysis. Above an NTA-measured



concentration of 5×10^8 particles mL^{-1} , the particle counts no longer doubled with a doubled incubation concentration; therefore, it was not clear if measured spots

were truly single EVs or fluorescence from multiple particles, also known as “swarming.”

To identify whether this apparent upper concentration limit was due to binding limitations (e.g., steric hindrance

or lack of available binding sites) or instead due to fluorescence overlap, the average fluorescent intensity of the particles at each concentration was identified. If measured spots are truly single particles, as incubation concentration increases, particle count should increase, but the fluorescent intensity of each particle should remain the same. Increasing incubation concentration incrementally from 4.0×10^7 to 2.5×10^8 particles mL^{-1} produced no significant increase in fluorescent intensity per bound particle. However, the incubation NTA-measured concentrations of 2.5×10^8 particles mL^{-1} , or ~ 2500 captured particles/spot in a single fluorescent channel, there was a significant increase in fluorescent intensity per bound particle (Fig. 2f). From this point forward, when analyzing protein expression, we limited number of captured particles per spot to ~ 2500 to ensure that all analyzed particles represented single EVs.

SK-OV-3 EVs consistently exhibit time-independent tetraspanin expression

Next we analyzed tetraspanin profiles for SK-OV-3 EVs isolated by UC. SK-OV-3 EVs expressed all three tetraspanins with varying co-expression of each. We measured discrepancies between capture and detection, even for the same tetraspanin. For example, the highest number of detectable EVs were captured by anti-CD9, although very few were detected by anti-CD9 on any capture spot (Fig. 3a, blue bars). On the other hand, the majority of EVs captured across each of the tetraspanins were detected by anti-CD81 in all cases (Fig. 3a, green bars). Compared to anti-CD81 capture, similar numbers of

EVs were captured by anti-CD63, yet notably fewer anti-CD63-captured EVs were detected by anti-CD9.

Next, we measured whether this profile was consistent amongst EVs isolated from cells grown in a bioreactor flask over the course of several weeks (Fig. 3b). The bioreactor allows for collection of EVs in volumes of ~ 15 mL from over 2.5×10^7 cells in 3D culture with minimal upkeep, and has been adopted by multiple labs [27, 31]. Since this or similar methods will likely be utilized for scale-up in industrial application, it is important to identify the consistency of EVs from this type of system from consecutive harvests. Although EVs from each week were incubated at 2.5×10^8 particles/mL on each chip, the total number of fluorescently identified EVs varied by week. For example, CD81 capture/CD81 detection ranged from 1000 to 4500 total particles depending on the week. This may have been due to low precision associated with NTA derived concentrations used to inform chip incubation concentration. For this reason, we normalized the tetraspanin profiles of the EVs from each week to the total number of EVs detected in at least one fluorescent channel per chip (Fig. 3b). Therefore, when normalized to be independent of total EV yield over the course of 6 weeks, SK-OV-3 EVs showed relatively low variability in tetraspanin profile, with less than a 5% standard deviation for most capture/detection combinations. One exception was detection of anti-CD81 for particles captured by anti-CD81, with a slightly higher variation of 7.68% across 6 weeks. EVs produced from SK-OV-3 across different bioreactors from various cell passages were tested and showed similar tetraspanin profiles (Additional file 1: Figure S2).




Fig. 3 Fluorescence profiling of tetraspanin expression for isolated SK-OV-3 EVs. **a** Representative example of tetraspanin colocalization for SK-OV-3 EVs isolated by UC after 1 week of cell growth in a bioreactor flask. **b** Tetraspanin colocalization pattern of SK-OV-3 EVs remained relatively consistent across 6 consecutive weeks of isolation by UC from bioreactor grown cells. Tetraspanin colocalization pattern of SK-OV-3 EVs from week 6 of the bioreactor isolated by **(c)** UC or **(d)** SEC showed some differences but did not have variation outside that seen from week to week of the bioreactor isolations. N = 3 capture spots. Error bars represent \pm one s.d

Effect of isolation method and biofluid source on tetraspanin profile

Given the reported effects on EV composition according to isolation methodology [32, 33], we measured EV tetraspanin profile using SEC or UC. After UC, SEC is the next most common method to isolate EVs according to a recent poll [26]. To directly compare UC to SEC, conditioned media from the bioreactor containing SK-OV-3 cells at week 6 was split in half and isolated either by UC or SEC. EVs isolated from either method exhibited a similar tetraspanin profile i.e., for each capture spot, the particle count of each tetraspanin followed the same relative trend (Fig. 3c, d). Notably, total counts by anti-CD63 capture increased for SEC isolated EVs, while the number of anti-CD81 captured particles decreased. However, these differences were not outside of the week-to-week variation of bioreactor samples isolated by UC (Fig. 3b).

After identifying that SK-OV-3 EVs had a consistent tetraspanin profile across different isolation weeks and different isolation techniques, we expanded to other biofluid sources to find if this trend is indicative of all EVs. We isolated EVs from PMSCs, chosen for clinical applicability. MSC-derived EVs have a variety of therapeutic effects and have been of great interest for treating numerous diseases. PMSC EVs in particular have

neuroprotective properties and are being studied for treatment of spina bifida and multiple sclerosis [34–36]. We also isolated EVs from human serum, to represent a more complex source with relevance to diagnostic analysis.

Each EV source has heterogeneous apparent tetraspanin profiles depending on capture antibody (Fig. 4a–c). Detection of EVs by fluorescent antibody was compared both by the total number of fluorescent particles on any capture spot (Fig. 4d) or separated by specific capture spot (Fig. 4e). While some differences in anti-CD9 and anti-CD81 detection were apparent independent of capture spot, there was no significant difference in CD63 detection (Fig. 4d). However, when separated by capture spot, there are distinct differences in multiplexed tetraspanin expression, suggesting that distinct subpopulations exist that are unique to each source (Fig. 4e). Serum EVs exhibited relatively high anti-CD9 detection (Fig. 4d), with a particularly distinct anti-CD9 capture/anti-CD9 detection peak (Fig. 4e). This suggested that serum EVs exhibit a higher density of co-expressed CD9, since EVs were detected in higher numbers by anti-CD9 compared to SK-OV-3 EVs (Fig. 4a, b). In vitro isolated PMSC EVs had a tetraspanin profile more similar to SK-OV-3 EVs with similar distinct CD9 capture and CD9/CD63/CD81




Fig. 4 Comparison of tetraspanin profile of EVs isolated by UC from varying biofluid source. Representative EVs derived from (a) SK-OV-3, b serum, and c PMSCs exhibit distinct tetraspanin profiles. N = 3 technical replicates representing 3 capture spots each. Three samples of EVs from each source were analyzed and the average fraction of total fluorescent particles was determined for detection antibody on (d) any capture spot or (e) single capture spot. This highlights the complex nature of tetraspanin multiplexing. N = 3 experimental replicates representing 3 capture spots each. Error bars represent \pm one s.d. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ by ANOVA

detection profiles (Fig. 4e). However, PMSC EVs had a higher percentage of EVs that were detected by anti-CD9 (Fig. 4d), suggesting that CD9 was more densely expressed on PMSC EVs compared to SK-OV-3 EVs, which was mainly due to CD81 captured EVs (Fig. 4e).

Single particle flow cytometry to complement tetraspanin expression

Nanoscale flow cytometry is a complementary technique to analyze single-EV protein expression. In comparison to fluorescence microscopy of EVs by ExoView, flow cytometry is much higher throughput, allowing interrogation of ~100,000 particles min⁻¹ with a variety of options for fluorescence detection (more light sources/filters). The main drawback of flow cytometry is that it is scatter limited, producing a theoretical limit of detection of ~80 nm for EVs in the best case. We directly compared tetraspanin expression of the aforementioned various EV populations between SP-IRIS and nanoscale flow cytometry to compare apparent tetraspanin profiles.

Prior to analysis of EVs, we calibrated the flow cytometer using a variety of standard refractive index, size, and fluorescent beads, as described by Welsh et al. [37]. This allows us to produce standardized, calibrated data and to optimize the instrument for detecting

nanoparticles [22, 38]. To better visualize the limit of detection, the 405 nm SSC-H threshold was chosen to visualize approximately 1000 events s⁻¹ of electronic noise (Fig. 5a). This procedure permits tuning of the detection threshold above the electronic noise to maximize the number of detected EVs. For light scatter calibration, we analyzed the scattering intensity of a variety of polystyrene beads. These scattering intensities of beads of known diameter could then be used to estimate the size of particles of constant refractive index based on Mie scattering theory using publicly available FCM_{PASS} software. Using this software and optimized gains, we determined our instrument’s theoretical detection limit by transforming the arbitrary units of SSC intensity to units of size, assuming a constant refractive index (details shown in Additional file 1: Figure S3) [37]. With a threshold of 900 for triggering by SSC-A, we found that our reliable limit of detection when gating for EVs above instrument noise was ~100 nm (Fig. 5b).

To ensure that events were single EVs and not “swarming” EVs [39] (multiple EVs being interrogated at one time producing a single event) labeled SK-OV-3 EVs were diluted in series. At all concentrations tested, total events decreased linearly with dilution, while scatter intensity




Fig. 5 **a** Histograms of side scatter area (SSC-A) of control PBS, showing the gating choice above electronic noise and below impurities, and SK-OV-3 EVs, showing the additional events both within and above the noise limit. **c** Histogram of SK-OV-3 EV size converted to diameter using FCM_{PASS} calibration. **d** Dilution series of SK-OV-3 EVs illustrating constant median fluorescent intensity (MFI, violet circles) as events increased with concentration (gray squares), confirming that detected events are single particles in the concentration range tested. **d** Total number of fluorescent particles above background for labeled EVs versus antibody control. **e** Percent of total fluorescent EVs identified by each tetraspanin. Error bars represent ± one s.d. * p < 0.05, ** p < 0.01, *** p < 0.001 by Student’s t-test versus Ab control for (d) and ANOVA for (e). N = 3 experimental replicates

remained constant, suggesting that at these concentrations, events represented single EVs (Fig. 5c).

SK-OV-3, PMSC, and serum-derived EVs were analyzed for tetraspanin expression using the same fluorescently-labeled detection antibodies for the preceding ExoView experiments, to minimize any variability as a result of batch-to-batch differences. A final concentration of 5×10^8 particles mL^{-1} , measured by NTA, was utilized for SK-OV-3 and PMSC EVs. Serum EVs were analyzed at 5×10^9 particles mL^{-1} to achieve the same counts, likely due to co-isolated non-EV particles (e.g., lipoprotein particles) that are indiscernible from EVs by NTA. Gating schemes were chosen above background noise (Additional file 1: Figures S4 and S5). For SK-OV-3, PMSC, and serum-derived EVs, respectively, 19,600, 19,100 and 64,900 events, representing 2.5%, 1.3%, and 13.6%, of all events above background SSC intensity were above background fluorescence intensity in one or more channels.

Student's t-tests were applied to assess statistical significance of detected events compared to the background noise events. For all tetraspanins, PMSC EVs had a significantly higher percentage of EVs above background (Fig. 5d). Both SK-OV-3 and serum-derived EVs had populations of EVs that were discernable above non-labeled EVs and antibody only controls, although close to the limit of detection. Notably, SK-OV-3 CD9+ and CD81+ EVs were not statistically significant to the number identified in the antibody only control mainly due to low counts in one of the three replicates. The low amount of highly fluorescent CD9+ EVs was similar to the trends seen with SP-IRIS. Similar to our approach to display this complex multiplexing data in Fig. 4e above, Fig. 5e shows a complementary plot of the flow cytometry data with counts normalized to total particles, in order to visualize relative trends of detected particles. Serum EVs showed similar protein expression by flow cytometry and immunocapture, with the smallest fraction of EVs being CD81+. However, flow cytometry did not produce an apparent profile of PMSC EVs that was similar to immunocapture. For flow cytometry, although there were more CD81+ EVs compared to CD63+ EVs, the largest fraction was CD9+. By immunocapture, the fewest number of EVs were detected by CD9 fluorescence.

Non-specific EV capture and profiling by EV biotinylation

For serum and PMSC derived EVs, EVs captured by different tetraspanins had distinct apparent fluorescent tetraspanin profiles. From this, we hypothesized that non-specific capture would provide a more encompassing view of the tetraspanin profile of the entire population. To this end we aimed to non-specifically capture EVs via covalent biotinylation of exposed amine groups


on EVs' surface protein similar to Kee et al. [40]. Customized chips were obtained from NanoView with an anti-biotin coating to facilitate non-specific capture. Biotinylated-EVs were separated from unbound biotin by SEC. Purified, biotinylated EVs were incubated on the anti-biotin coated chip and probed with the same tetraspanin detection panel used throughout the study, anti-CD9, anti-CD63, and anti-CD81 (Fig. 6a). More EVs were detected on anti-biotin capture spots compared to anti-CD81 capture spots, which had the most numerous captures of any tetraspanin spot. These appeared to be true biotinylated EVs, as non-biotinylated EVs nor the biotinylation agent itself identified any fluorescent particles. Furthermore, the biotinylation did not appear to significantly impact the apparent tetraspanin profile in most cases when compared to a non-biotinylated sample (e.g., Fig. 6a "EV" vs "B-EV").

Serum and PMSC derived EVs were also biotinylated and analyzed. Serum EVs, unlike SK-OV-3 EVs, did not show an overall increase in capture by anti-biotin compared to each single tetraspanin, but were captured as efficiently by anti-CD9 as by anti-biotin (Fig. 6b). Furthermore, the apparent tetraspanin profile appeared similar to that of the CD9 capture spot. PMSC EVs had a higher number of particles captured by anti-biotin than any single tetraspanin (Fig. 6c). However, the apparent tetraspanin profile did not match any of the single tetraspanins, having a similar number of EVs detected by CD63 and CD81, and a lower number detected by CD9.

OvCa markers on EVs captured non-specifically or by single tetraspanins

Circulating EVs are attractive next generation diagnostic biomarkers due to the fact that their biochemical signatures are indicative of their origin (are subsets of their parent cell) and disease state. EVs from epithelial OvCa are on the leading front of this research, and often are used as a model to show proof-of-concept for EV biosensing platforms. Yet there is little known about the heterogeneity of the diagnostically relevant markers on these EVs. For this reason, we wanted to identify if multiplex bias by tetraspanin capture could affect the identification of diagnostically relevant proteins on SK-OV-3 EVs. Three markers frequently associated with OvCa, CD24, EpCAM, and Her2 [41], have also been utilized to identify the diagnostic efficacy of OvCa EVs [42, 43].

SK-OV-3 EVs were biotinylated and incubated with chips as previously described, and then labeled with fluorophore-conjugated anti-CD24, anti-EpCAM, and anti-Her2 detection antibodies (Fig. 7a). CD24+ EVs were detected at a similar frequency on anti-CD9 and anti-biotin capture spots. However, anti-CD63 and anti-CD81 did not have a significant number of




captured EVs above the MIgG control spot. Although EpCAM+ EVs could be detected on all three tetraspanin capture spots at similar rates, biotin capture identified more EVs by approximately a tenfold difference. Her2+ EVs were identified with high frequency on all tetraspanin spots with approximately 5 times as many detected on the anti-biotin capture spot. We reason then that non-specific capture can greatly increase the capture of EVs that are expressing tumor markers, compared to specific capture by a given tetraspanin (Fig. 7b).

Discussion

Although EV-related research has grown exponentially in recent years, many basic questions remain, particularly related to compositional heterogeneity. Specifically, protein multiplex bias, which we define as the enrichment of EVs by a specific protein, may be limiting in the absence of accepted, universal exosome-exclusive markers. Understanding protein expression patterns across the true distribution of EVs will be vital to making informed decisions on use of EV capture for many applications.

EVs from different sources have varying tetraspanin profiles

We isolated EVs from a variety of sources to determine single-EV tetraspanin colocalization patterns, including a cultured OvCa cell line (SK-OV-3), human serum, and cultured PMSCs. In all cases, we found that tetraspanin expression was not homogeneous across a single population of EVs, with varying number of EVs captured by each tetraspanin. In addition, we found that EVs from the same biofluid source, independent of isolation technique, had consistent tetraspanin colocalization profiles. However, this tetraspanin colocalization profile differed between EV sources, with SK-OV-3, PMSC, and serum derived EVs all exhibiting unique expression patterns. Serum EVs had the most similar profile to SK-OV-3 EVs but had a significantly higher percentage of anti-CD9 detected EVs on anti-CD9 and anti-CD63 capture spots. PMSC derived EVs had a much more unique tetraspanin profile with a higher anti-CD63 capture/anti-CD63 detection and anti-CD81 capture/anti-CD9 detection. In general, this supports that protein multiplex bias, even by a well-known EV associated marker, can impact the apparent protein expression within an EV population.



Here we corroborated previous reports that there are differences in tetraspanin profile between different EV sources [3, 44, 45]. Yet few have measured multiplexed tetraspanin expression. Kowal et al. used bead-based immunocapture and successive Western blot to examine multiplex expression of tetraspanins [12]. This work showed that CD9 and CD81 were found on most dendritic cell EVs but are not necessarily co-expressed. However, CD63 was on a much smaller subpopulation which was always co-expressed with either CD9 or CD81. Our data did support that CD63 was generally a less common marker, given that either CD9 or CD81 almost always captured more EVs. However, since the number of CD63+EVs was not constant on each tetraspanin capture spot, we did not conclude that CD63 was always co-expressed with CD9 or CD81. This emphasizes the importance of understanding the specific profile of tetraspanins for a given EV source prior to utilizing any single tetraspanin for capture.

Apparent tetraspanin profiles vary between SP-IRIS and flow cytometry

Currently, single-EV protein analysis techniques are hampered by limits of detection which severely restrict the population of EVs that can be analyzed. These techniques are generally either protein biased, requiring presence of a single protein for capture, or size biased,

requiring a large enough size to be identified. While SP-IRIS, as performed here, is protein biased, requiring CD9, CD63, or CD81 to be present for analysis, the combination of these three EV-associated proteins helps to mitigate this limitation. On the other hand, flow cytometry, a useful technique for measuring single-EV protein expression, is scatter-biased. When the same EVs from each source were analyzed by flow cytometry, the acquired apparent tetraspanin profiles had variable agreement with those acquired by SP-IRIS, as described before. The lack of agreement between these two analysis techniques could be due to differences in sensitivity to the different fluorophores, because of un-bound antibody in the stream for flow cytometry, optics strength and collection efficiencies, or autofluorescence of the bound antibody. Although it is likely that this contributed to some of the differences in apparent tetraspanin profile, lack of major systematic bias, e.g., all “blue” fluorophores appearing more numerous, indicate it is only a minor effect. For example, anti-CD9 detection by flow cytometry decreased for serum EVs yet increased for PMSC EVs compared to immunocapture. Overall, using fluorescence-based detection, SP-IRIS is not limited by scatter of EVs, while flow cytometry can only see a small fraction of total EVs larger than 100 nm. This difference in the “visible” EVs that were analyzed may also be responsible for the difference in apparent tetraspanin expression.

In one previous study, EV tetraspanin expression varied with apparent EV density, i.e., scattering intensity, subpopulations [12]. Specifically, CD63 was restricted to a less dense population of EVs. Since these results do not show a homogeneous decrease in CD63 detection by flow cytometry compared to immunocapture, it is difficult to tell if density is a major factor in our study. Another explanation could be that density-dependent tetraspanin expression is not homogeneous across cell sources. Size-dependent expression could also explain the changes; however, to our knowledge no group has systematically studied correlation between EV size and tetraspanin expression at single vesicle resolution. Finally, the incubation concentrations of each technique are very different. To avoid swarming in flow cytometry, EVs must be diluted to only have one EV within the interrogation volume of the laser in the stream. For fluorescence detection on the ExoView, to avoid overlap of fluorescent signal from closely bound EVs, the concentration must be limited to avoid EVs binding within the diameter of the airy disc of the fluorescent signal from nearby EVs. Since single particle interrogation for each technique is limited by different factors (concentration vs. kinetics of binding) they each have different optimal concentrations. Nonetheless, the differences in apparent tetraspanin profile between immunocapture and flow cytometry emphasizes the importance of considering the technique specific limitations of EV analysis. In summary, flow cytometry may be more appropriate for high-throughput needs, while immunocapture/fluorescence likely provides a more holistic protein expression due to its ability to visualize smaller particles in general.

Non-specific EV capture decreases multiplexing bias in diagnostic application

There is increasing interest in using EVs as diagnostic tools due to their reflection of parent cell markers and their presence in multiple biofluids, decreasing invasiveness of diagnostic procedures. OvCa diagnosis is a prime candidate for next generation EV-screening since CA-125 ELISA, the current clinical gold standard, lacks both sensitivity and specificity, resulting in high rates of false-positives and overwhelmingly late-stage diagnosis [46]. Multiple groups have identified specific markers associated with OvCa on OvCa EVs including CD24, EpCAM, and Her2 [42, 43]. Currently, many cancer diagnostics rely on a primary capture antibody, often a tetraspanin, and use a secondary label for EV-associated markers [47–49], including for OvCa [42].

Although tetraspanins are well-known EV-associated markers, multiple groups have shown that these markers are not necessarily ubiquitous on EVs [3, 44, 45], but that their expression changes with EV subclass, size, and

source. We reasoned that capture by tetraspanin may bias downstream multiplexed marker detection, given our initial findings of high heterogeneity in tetraspanin expression for different sources of EVs. To explicitly test this, we chemically modified EVs to incorporate biotin at their surface, as a handle for non-specific capture by anti-biotin. While some groups have used this method for non-specific capture, none have compared this to capture by EV-associated proteins, making it difficult to draw conclusions on which method. Perhaps unsurprisingly, we found that anti-biotin was consistently able to capture at least as many or more EVs than any single tetraspanin. Unexpectedly, we found that SK-OV-3 EVs expressing CD24 were only multiplexed with CD9 (but not CD63 nor CD81). On the other hand, EpCAM and Her2 had a similar number of EVs captured by each tetraspanin. However, significantly more EpCAM and Her2 expressing SK-OV-3 EVs were detected when capturing non-specifically. This suggests that there may be a large percentage of non-tetraspanin expressing EVs that contain the bulk of these markers. Together these data show that single-tetraspanin capture of EVs can impact the efficiency and sensitivity of detection of these diagnostically relevant markers. This suggests that the multiplexing efficiency of disease markers with specific tetraspanins should be studied prior to choosing a single protein for capture. A combination of tetraspanins can be used to avoid bias or a non-specific capture method can be utilized as carried out here.

In the context of diagnostic platforms, non-specific capture may be able to increase sensitivity to markers. However, since biofluids contain free protein, lipoprotein, and many other particles, single step biotinylation could lead to many biotinylated non-EV particles blocking capture of biotinylated EVs. It may be necessary to pre-treat biofluids for isolation of EVs from non-EV particles to use this non-specific capture method. In addition, EVs from other sources such as platelets may decrease the sensitivity. Future groups should consider including in-system isolation [50, 51], and sensitivity testing to determine if biotinylation can effectively increase sensitivity for a given application.

The goal of this study was to determine the bias associated with single-tetraspanin capture of EVs. Here, we show that although EVs from a single source have consistent multiplexing patterns of tetraspanins regardless of isolation technique and passage, tetraspanins are not homogeneously expressed on every EV. This shows that EV subpopulations exist with unique tetraspanin density and multiplexing even from a single cell source, such that capture by a single tetraspanin type could inadvertently bias downstream profiling. Moreover, tetraspanin density and frequency was unique for different clinically relevant

sources of EVs. This emphasizes that EV capture by any given antibody needs to be informed by careful characterization of the protein profile of a given EV source. Furthermore, we confirmed that non-specific EV capture by anti-biotin can be achieved by biotinylation of EVs. This allowed us to identify significant bias in apparent tetraspanin expression by single-tetraspanin captured EVs from both serum and PMSCs. Finally, when detecting OvCa markers on SK-OV-3 derived EVs, we identified that CD24 could only be identified by CD9 or non-specific capture, and that EpCAM and Her2 detection were more sensitive by non-specific capture. This work demonstrates that non-specific biotinylation may allow for less biased multiplexed analysis of EVs in diagnostics platforms and untangles some of the complex nature of EV protein expression. Careful consideration of EV-capture methods is necessary to maximize accurate and sensitive detection of multiplexed markers.

Materials and methods

All chemical reagents and supplies were purchased from Millipore Sigma unless noted.

EV generation and collection

The CELLline 1000AD bioreactor was utilized to maximize concentration of SK-OV-3 EVs and minimize processing steps as described previously [27, 28]. SK-OV-3 cells at passage 6 were plated and expanded in flasks to reach the minimum of 2.5×10^7 cells required to seed the bioreactor. McCoy's 5A, 1X (Iwakata and Grad Mod.) with L-glutamine supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin were used for media during expansion. At passage 9, 2.7×10^7 SK-OV-3 cells were seeded in the cell compartment of a CELLline 1000AD bioreactor in 15 mL of supplemented media. 1L of McCoy's 5A, 1X (Iwakata and Grad Mod.) with L-glutamine supplemented with only 1% penicillin/streptomycin was added to the media compartment. After 24 h to ensure full adhesion of cells to the matrix in the cell compartment, cell compartment media was replaced with EV-depleted media. EV-depleted media was prepared by centrifuging McCoy's 5A, 1X (Iwakata and Grad Mod.) with L-glutamine supplemented with 10% FBS overnight at $100,000 \times g$. 1% penicillin/streptomycin was then added, and the media was filtered. After seven days the cell compartment media was extracted to collect EVs and replaced with EV-depleted media, and the media in the media compartment was also replaced. This was repeated each week for a total of 6 weeks.

Placental mesenchymal stem cells (PMSCs) were isolated and expanded as previously described [36]. Briefly, PMSCs were isolated from de-identified second trimester human placenta from the chorionic villus after explant

culture. These cells were expanded in HyClone Medium high glucose supplemented with 5% fetal bovine serum, 20 ng mL^{-1} basic fibroblast growth factor, 20 ng mL^{-1} epidermal growth factor, and 1% penicillin/streptomycin and expanded at low passage numbers. 48–96 h prior to EV collection, cells were collected, washed with phosphate buffered saline (PBS) and reseeded with EV depleted media as prepared above. Conditioned media was collected from PMSCs at passage 4 from 20 to 35 T150 flasks. Controls were performed to ensure that EV depletion of FBS containing media depleted signal from bovine EVs and that small differences in isolation procedure did not affect apparent protein profiles (Additional file 1: Figure S6).

Serum samples were provided by the UC Davis Comprehensive Cancer Center biorepository as deidentified remnants, obtained from patients who received a clinician-ordered CA-125 test. From each patient, ~2 mL of serum was obtained.

EV isolation

Ultracentrifugation

To isolate EVs, we followed ultracentrifugation isolation procedures recently reported (Method I) [25]. Cell culture supernatant (15 mL) or serum (1 mL) was centrifuged at $300 \times g$ for 10 min at 4°C to remove any cells and large debris. The EV containing supernatant was collected and centrifuged at $2000 \times g$ for 15 min at 4°C to remove apoptotic bodies and debris. The supernatant was further subjected to $10,000 \times g$ for 30 min at 4°C to remove larger microvesicles. This supernatant was spun twice at $120,000 \times g$ for 70 min at 4°C , with the pellet resuspended in DI water in between spins. The final supernatant was discarded, and the pellet resuspended in MilliQ water or PBS (125–225 μL). This solution was aliquoted and frozen at -80°C until used. Freeze-thaw cycles were minimized for downstream application. Centrifuge steps for SK-OV-3 samples were completed in an Optima LE-80K centrifuge with a SW-28 rotor. Slow speed centrifuge steps for serum samples were completed a Beckman Coulter Microfuge 20R centrifuge with an FA361.5 Biosafe rotor and slow speed spins were completed in a Beckman Optima TLX Ultracentrifuge with a TLA 100.1 fixed angle rotor.

PMSC EVs followed the same general protocol with two minor differences (Method II). First, after the $2000 \times g$ spin two filtration steps were added. The supernatant was transferred to a $0.2 \mu\text{m}$ filter and vacuum filtered. The EVs in the filtrate were then concentrated in sterilized Centriprep 100,000 K cutoff filters at $8836 \times g$ for 30 min, adding additional media until all media had been concentrated, before continuing on to the $10,000 \times g$ spin. Finally, the samples were subjected to $120,000 \times g$ for 90 min each

instead of 70 min during the last two steps. Centrifuge steps for PMSC samples were completed in an L7 Ultracentrifuge with an SW-28 rotor (Beckman Coulter).

All EV samples were aliquoted to minimize freeze-thaw cycles and stored at -80°C until used.

Size exclusion chromatography (SEC)

Prior to SEC, samples were centrifuged as described in the ultracentrifugation isolation methods through the $10,000\times g$ spin. Izon 70 nm qEV_{single} columns were utilized in the Izon Automatic Fraction Collector (AFC). Columns were rinsed using $0.2\ \mu\text{m}$ -filtered PBS (4 mL). After rinsing, any remaining solution was removed from the top of column, $150\ \mu\text{L}$ of sample was placed on top of the column and allowed to enter before adding filtered PBS. After void fraction elution, 2 fractions ($0.2\ \text{mL}$ each) were collected that were confirmed to contain EVs in prior experiments. These fractions were combined and frozen at -80°C until used. Since the volume of sample was limited to $150\ \mu\text{L}$, EVs isolated by this procedure were analyzed at a lower dilution for later characterization but did not need to be pooled.

EV characterization

Nanoparticle tracking analysis (NTA)

EVs were diluted in DI water to be analyzed by the NanoSight LM10 (Malvern Panalytical Ltd., UK) for size and concentration determination. The instrument was equipped with a 405 nm laser module and sCMOS camera. The NanoSight tubing was rinsed with filtered water prior to use. An accompanied automated syringe pump (Harvard Bioscience, MA, USA) allowed for recording a statistically representative portion of the EV isolate in flow conditions instead of recording the videos in a stagnant view. The particle concentrations were diluted to 1×10^8 and 1.6×10^9 particles mL^{-1} in order to acquire an optimal readout for the data processing. The average concentration was also used for ExoView chip dosing. $3\times 30\ \text{s}$ videos were obtained at camera level 10–11, and the data was analyzed using NanoSight NTA 3.1. software (detection threshold 2–3).

Transmission electron microscopy

Stock EVs were diluted 1:1 in 4% paraformaldehyde. A drop ($10\ \mu\text{L}$) of this solution was placed on the back side of parafilm covering a glass slide. A copper TEM grid was then floated on top of the EV solution for 20 min at room temperature. The grid was transferred to a drop ($100\ \mu\text{L}$) of TEM grade PBS to wash and then quickly to 2% glutaraldehyde for 5 min. The grid was then transferred to 8 successive DI water drops ($100\ \mu\text{L}$) for 2 min each to wash. The grid was then transferred to a drop of uranyl oxalate ($50\ \mu\text{L}$) for 5 min. Each grid was then dried

by wicking the solution on filter paper. EVs were then imaged by transmission electron microscopy on a Talos L120C (Thermo Fisher Scientific, MA, USA) within 24 h.

Western blot

EV pellets were lysed in RIPA lysis buffer containing protease inhibitor cocktail (Roche). A total of $2\ \mu\text{g}$ of protein per lane was loaded on a 4–12% graded Tris-glycine SDS-polyacrylamide gel and proteins were transferred to a $0.2\ \mu\text{m}$ PVDF membrane (Life Technologies). Membranes were blocked in 5% milk in PBS with 0.05% Tween-20 for one hour at room temperature with rocking, and then incubated with primary antibody in blocking buffer at 4°C overnight. Antibodies to CD9 were used at 1:1000 dilution (BioLegend), CD63 at 1:1000 dilution (BD Biosciences), and CD81 (Santa Cruz Biotechnology) at 1:500 dilution. Secondary antibody mouse IgGκ-HRP was diluted at 1:5000 in block buffer and incubated at 1 h at room temperature with rocking (Santa Cruz Biotechnology). Proteins were visualized with Supersignal West Pico PLUS chemiluminescent substrate (ThermoFisher) using a KwikQuant imager (Kindle Biosciences).

ExoView tetraspanin kit assay

ExoView Kits were used as purchased (NanoView Biosciences) to interrogate EVs. All chips were stored at 4°C when not in use and allowed to warm to room temperature prior to use. Chips were pre-scanned using the provided protocol to identify any previously adhered particles during manufacturing. For incubation, chips were placed in wells of a 24 well plate, avoiding contact of the chip corners with the sides of the well. Water was added to the void space of the 24 well plate to dampen vibrations. EVs were diluted to the stated concentration, or at least 1:1, in the provided Incubation buffer and this solution ($35\ \mu\text{L}$) carefully pipetted directly onto each chip, avoiding allowing the solution to spill off the edges. The plate was then covered in aluminum foil and allowed to incubate at room temperature overnight. The following morning, 1 mL of incubation solution was added to each chip and the plate was shaken at 500 rpm for 3 min. Solution ($750\ \mu\text{L}$) was removed from each well, replaced with new incubation solution, and shaken at 500 rpm for 3 min. This was repeated twice more for a total of 4 shake steps. During shake steps, detection antibody solution was prepared by combining incubation solution and blocking solution in a 2:1 ratio and adding each of the provided tetraspanin antibodies in a ratio of $1\ \mu\text{L}:600\ \mu\text{L}$ solution. The provided tetraspanin panel includes: CF488-anti-CD9 (clone: HI9a), CF647-anti-CD63 (clone: H5C6), and CF555-anti-CD81 (clone: JS 81). After the last shake, $750\ \mu\text{L}$ of solution was removed and $250\ \mu\text{L}$ of antibody solution was added to each well. The plate

was covered in aluminum foil and allowed to incubate at room temperature for 1 h. After incubation, incubation solution (500 μL) was added to each well. Immediately following, solution was removed from each well and replaced with new incubation solution (750 μL). The plate was then shaken at 500 rpm for 3 min. This was repeated 3 times with wash solution and once with rinse solution. Two petri-dishes were filled with rinse solution and each chip was transferred with flat tip tweezers from the 24 well plate to the first dish, swirled, then to the second dish and swirled. During each transfer, care was taken to ensure the chip remained flat so that the antibody array remained wet. Chips were dried by tipping the chip at a 45° angle, slowly lifting out of solution, and placing on Kim wipe. The chips were then transferred to the chuck and scanned for interferometric and fluorescence imaging. During data analysis, fluorescence cut-offs were chosen by limiting the number of detected particles on MIgG capture spots to approximately 10 events. For the tetraspanin antibodies, we used fluorescence cut-offs of 400 a.u. for the red and green channels and 600 a.u. for the blue channel in all experiments.

For ovarian cancer marker staining, AlexaFluor 488 anti-human CD326 (EpCAM) (clone: 9C4), PE anti-human CD24 (clone: ML5), and AlexaFluor 647 anti-human CD340 (HER-2) (clone: 24D2) were incubated at 1 $\mu\text{g mL}^{-1}$ in blocking solution. Fluorescence cut-offs of 600 a.u., 300 a.u., and 300 a.u. were used for the blue, green, and red channels, respectively. This panel of antibodies was purchased from BioLegend.

Flow cytometry

A CytoFLEX flow cytometer (Beckman Coulter) equipped with four lasers was used for all flow cytometry experiments. Prior to EV analysis, we employed a calibration procedure utilizing standard beads and FCM_{PASS} software described recently by Welsh et al [22]. For size calibration, we utilized a mixture of NIST Traceable polystyrene beads (ThermoFisher) including 100 nm, 152 nm, 203 nm, 269 nm, 345 nm, 401 nm, and 453 nm. 405 nm SSC was used for triggering and the threshold was set to achieve an event rate of approximately ~ 2000 events s^{-1} on the lowest flow rate of 10 $\mu\text{L min}^{-1}$ when analyzing 0.2 μm -filtered ultra-pure water. In this case the threshold was 1000 (a.u.) at a gain of 200. Beads were diluted in 0.2 μm -filtered water to reach a total event rate of approximately 10,000 events s^{-1} and recorded for 120 s. These data were analyzed in FCM_{PASS} software to convert the arbitrary scatter intensity to nominal diameter of particles [37]. Gain of the various channels was optimized by analyzing 8 Peak Rainbow Calibration Beads from Spherotech (Cat. RCP-30-5A). Gain was increased incrementally from 25 to 3000 in each channel. The gain

that best separated the dimmest bead population from background, calculated by stain index $((\text{MFI}_{\text{beads}} - \text{MFI}_{\text{background}}) / \text{Stdev}_{\text{background}})$, was chosen for further studies. Next, a combination of 200 nm and 500 nm fluorescent beads were utilized to optimize 405 nm SSC gain. This is a slight deviation from the procedure of Welsh et al. as they utilized 100 and 200 nm beads [22]. Here, 405 nm SSC-H was used to trigger with a threshold of 900. Gain of 405 nm SSC was increased incrementally from 1 to 300 and the value that maximized the separation of the background 405 nm SSC intensity from the 200 nm beads was chosen, with a secondary goal of maximizing separation of 405 nm SSC intensity of 200 nm and 500 nm beads.

For antibody titrations, 1.0×10^9 SK-OV-3 EVs were incubated with 0.5 μL – 8 μL of each antibody provided by NanoView, described in ExoView Tetraspanin Kit Assay methods, and diluted to a total volume of 50 μL . Each sample was allowed to incubate for 30 min at 4 °C before dilution in 0.2 μm -filtered PBS (up to 2 mL). Optics parameters for particle detection and thresholding were determined from the calibration and optimization as described above. Here we used 405 nm SSC to trigger with a threshold of 900 with a gain of 100 and the following fluorescent channel gains: 488 nm laser: 525/40 nm filter gain of 2000, 561 nm laser: 585/42 nm filter gain of 1500, 638 nm laser: 660/20 nm filter gain of 1000. This produced approximately 1000 events s^{-1} of noise and impurities when analyzing 0.2 μm -filtered PBS. EVs were analyzed at the lowest flow rate of 10 $\mu\text{L min}^{-1}$ for 3 min. 1 μL , 2 μL , and 3.5 μL of anti-CD9, anti-CD63, and anti-CD81 antibody, respectively, was found to be the best volume to maximize separation index. Using this volume, either 1.0×10^9 of SK-OV-3, PMSC, or serum EVs were incubated and analyzed in the same conditions described previously. In addition, a sample of 1.0×10^{10} serum EVs was incubated with antibodies, since lipoprotein co-isolated with EVs and can dramatically inflate the concentration when analyzed by NTA. In addition to the typical dilution to 2 mL, the SK-OV-3 EV sample was also analyzed at dilutions of 0.5 mL, 1 mL, 4 mL, and 8 mL to check for swarming, the interrogation of multiple EVs at a single time.

Biotinylation of EVs

Biotin was covalently coupled to free amines of exposed EV membrane proteins in a non-specific manner. To accomplish this, 10^9 – 10^{10} EVs (as assessed by NTA) were incubated with 0.5 mM EZ-Link™ Sulfo-NHS-LC-Biotin in 50 μL of PBS at room temperature for 30 min. Biotinylated EVs were diluted to 150 μL and separated from free biotin by SEC using qEV_{single} columns on the Izon AFC. The first fraction (0.2 mL) was diluted 1:20 with Solution A and incubated on chips as described.

Statistical methods

All experiments were performed in triplicate and error bars represent one standard deviation (s.d.) from the mean. Statistical significance was assessed using built-in functions of MATLAB 2020a Update 5 software. For comparison of two populations, a Student's t-test was used, while ANOVA was used for three or more populations.

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12951-021-00987-1>.

Additional file 1: Figure S1. EV sizing by TEM. At least 50 particles were analyzed in 3 each of 3 images taken of SK-OV-3 EVs isolated by UC. Diameter of individual particles was estimated in the Fiji package of ImageJ by circling deflated EVs, as seen by thin white lines overlaid on TEM images. **Figure S2.** SK-OV-3 EVs isolated from separate bioreactors. The tetraspanin profile of EVs from a first bioreactor (a), copied from Fig. 3 for comparison, is similar to the tetraspanin profile of SK-OV-3 EVs isolated from a second bioreactor (b). Although there is a difference in CD81 capture/CD81 detection, this change was common between consecutive weeks from a single bioreactor. **Figure S3.** FCM_{PASS} Refractive Index Parameters and Modeling. Using scatter of a variety of standard beads, the size of SK-OV-3 EVs was modeled using (a) these parameters for average EV refractive index and membrane thickness. (b) FCM_{PASS} model of SSC-H vs. diameter of EVs by measuring polystyrene bead SSC-H of varying sizes. **Figure S4.** Gating scheme for tetraspanin analysis. In row 1, EVs are gated from background noise by examining PBS versus an EV only control. In row 2, gates were used to separate the real events from those at the limits of fluorescence (at 0 fluorescence) to find the median fluorescent intensity of the EVs. In row 3, fluorescence-minus-one controls were used to gate fluorescent particles from unstained particles. In row 4 these gates were adjusted to encompass no more than ~5% of the antibody aggregates. In row 5, fully stained EVs are shown as an example of where these gates appeared on fluorescently labeled particles. **Figure S5.** Flow cytometry of EVs from various sources labeled with anti-tetraspanin antibodies. SSC-A vs (a) anti-CD9-CF488, (b) anti-CD63-CF647, and (c) anti-CD81-CF555 of control samples and labeled EVs. EV only sample is SK-OV-3 EVs. **Figure S6.** Controls show that tetraspanin expression profile is not biased by presence of bovine EVs from FBS or by small differences in ultracentrifugation isolation procedure. (a) McCoy's 5A, 1X (Iwakata and Grad Mod.) with L-glutamine supplemented with 10% FBS EV depleted overnight at 100,000×g and (b) SK-OV-3 conditioned media were subjected to the same UC Method I isolation procedure. (c) The same volume of SK-OV-3 conditioned media was subjected to UC Method II isolation procedure. All samples were diluted 500 × prior to completing tetraspanin analysis on the ExoView. (a) EV-depleted media showed relatively few detected EVs while both isolation methods had high numbers of EVs with similar patterns of tetraspanin expression.

Acknowledgements

We also would like to thank members of the Wang Lab at University of California Davis Health for their work collected and de-identifying PMSCs for this work. Thanks to Joshua Welsh at the NIH for training in single particle flow cytometry techniques, and further flow cytometry technical assistance from Ms. Bridget McLaughlin and Mr. Jonathan Van Dyke.

Authors' contributions

TB performed Western blot. HJK and HSS provided serum and PMSC EV samples. RPC aided in data analysis and interpretation and drafting of the manuscript. TR aided in preparation of additional bioreactors. RRM performed all other sample preparation, experiments, data analysis, and manuscript preparation. All authors read and approved the final manuscript.

Funding

R.P.C. was supported by a Research Scholar Grant, RSG-19-116-01-CDD, from the American Cancer Society. T.R. gratefully acknowledges The Sigrid Juselius Foundation, Helsinki, Finland. This work was supported by funds from the Ovarian Cancer Education and Research Network (OCERN), the NIH National Institute of Neurological Disorders and Stroke (1R01NS115860), and the NIH National Cancer Institute (1R01CA241666). Specimens were provided by the UC Davis Pathology Biorepository which is jointly funded by the UC Davis Comprehensive Cancer Center Support Grant (CCSG) awarded by the National Cancer Institute (NCI P30CA093373) and the UC Davis Department of Pathology and Laboratory Medicine. This project was also supported by the University of California Davis Flow Cytometry Shared Resource Laboratory with funding from the CCSG award above, the S10 OD018223 (Astrios Cell Sorter), and S10 RR 026825 (Fortessa Cytometer) grants. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Availability of data and materials

The dataset(s) supporting the conclusions of this article is(are) available in the Zenodo repository: <https://doi.org/10.5281/zenodo.5189322>

Declarations

Ethics approval and consent to participate

Human samples were provided by the UC Davis Comprehensive Cancer Center biorepository as deidentified remnants, thus not qualifying as research involving human subjects as determined by the UC Davis IRB Administration (IRB ID: 1314848-1).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

¹Department of Biomedical Engineering, University of California, Davis, USA. ²Department of Pathology, University of California, San Diego, USA. ³Department of Surgery, University of California, Davis, USA. ⁴Division of Gynecologic Oncology, University of California Davis Medical Center, Sacramento, CA, USA.

Received: 28 May 2021 Accepted: 4 August 2021

Published online: 21 August 2021

References

1. Logozzi M, De Milito A, Lugini L, et al. High levels of exosomes expressing CD63 and Caveolin-1 in plasma of melanoma patients. *Cao Y, ed. PLoS One*. 2009;4(4):e5219. <https://doi.org/10.1371/journal.pone.0005219>.
2. Duijvesz D, Versluis CYL, van der Fels CAM, et al. Immuno-based detection of extracellular vesicles in urine as diagnostic marker for prostate cancer. *Int J Cancer*. 2015;137(12):2869–78. <https://doi.org/10.1002/ijc.29664>.
3. Campos-Silva C, Suárez H, Jara-Acevedo R, et al. High sensitivity detection of extracellular vesicles immune-captured from urine by conventional flow cytometry. *Sci Rep*. 2019;9(1):1–12. <https://doi.org/10.1038/s41598-019-38516-8>.
4. Suárez H, Gámez-Valero A, Reyes R, et al. A bead-assisted flow cytometry method for the semi-quantitative analysis of Extracellular Vesicles. *Sci Rep*. 2017;7(1):1–11. <https://doi.org/10.1038/s41598-017-11249-2>.
5. Chen YS, Ma YD, Chen C, Shiesh SC, Bin LG. An integrated microfluidic system for on-chip enrichment and quantification of circulating extracellular vesicles from whole blood. *Lab Chip*. 2019;19(19):3305–15. <https://doi.org/10.1039/c9lc00624a>.
6. Zhou S, Hu T, Zhang F, et al. Integrated microfluidic device for accurate extracellular vesicle quantification and protein markers analysis directly from human whole blood. *Anal Chem*. 2020;92(1):1574–81. <https://doi.org/10.1021/acs.analchem.9b04852>.

7. Chairoungdua A, Smith DL, Pochard P, Hull M, Caplan MJ. Exosome release of β -catenin: a novel mechanism that antagonizes Wnt signaling. *J Cell Biol*. 2010;190(6):1079–91. <https://doi.org/10.1083/jcb.201002049>.
8. Pols MS, Klumperman J. Trafficking and function of the tetraspanin CD63. *Exp Cell Res*. 2009;315(9):1584–92. <https://doi.org/10.1016/j.yexcr.2008.09.020>.
9. Wubbolts R, Leckie RS, Veenhuizen PTM, et al. Proteomic and biochemical analyses of human B cell-derived exosomes: potential implications for their function and multivesicular body formation. *J Biol Chem*. 2003;278(13):10963–72. <https://doi.org/10.1074/jbc.M207550200>.
10. Théry C, Witwer KW, Aikawa E, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. *J Extracell Vesicles*. 2018. <https://doi.org/10.1080/20013078.2018.1535750>.
11. Escola JM, Kleijmeer MJ, Stoorvogel W, Griffith JM, Yoshie O, Geuze HJ. Selective enrichment of tetraspan proteins on the internal vesicles of multivesicular endosomes and on exosomes secreted by human B-lymphocytes. *J Biol Chem*. 1998;273(32):20121–7. <https://doi.org/10.1074/jbc.273.32.20121>.
12. Kowal J, Arras G, Colombo M, et al. Proteomic comparison defines novel markers to characterize heterogeneous populations of extracellular vesicle subtypes. *Proc Natl Acad Sci U S A*. 2016;113(8):E968–77. <https://doi.org/10.1073/pnas.1521230113>.
13. Barranco I, Padilla L, Parrilla I, et al. Extracellular vesicles isolated from porcine seminal plasma exhibit different tetraspanin expression profiles. *Sci Rep*. 2019. <https://doi.org/10.1038/s41598-019-48095-3>.
14. Koliha N, Wiencek Y, Heider U, et al. A novel multiplex bead-based platform highlights the diversity of extracellular vesicles. *J Extracell Vesicles*. 2016. <https://doi.org/10.3402/jev.v5.29975>.
15. van der Pol E, Coumans FAW, Grootemaat AE, et al. Particle size distribution of exosomes and microvesicles determined by transmission electron microscopy, flow cytometry, nanoparticle tracking analysis, and resistive pulse sensing. *J Thromb Haemost*. 2014;12(7):1182–92. <https://doi.org/10.1111/jth.12602>.
16. Brisson AR, Tan S, Linares R, Gounou C, Arraud N. Extracellular vesicles from activated platelets: a semiquantitative cryo-electron microscopy and immuno-gold labeling study. *Platelets*. 2017;28(3):263–71. <https://doi.org/10.1080/09537104.2016.1268255>.
17. Park YH, Shin HW, Jung AR, et al. Prostate-specific extracellular vesicles as a novel biomarker in human prostate cancer. *Sci Rep*. 2016. <https://doi.org/10.1038/srep30386>.
18. Dickens AM, Tovar-Y-Romo LB, Yoo SW, et al. Astrocyte-shed extracellular vesicles regulate the peripheral leukocyte response to inflammatory brain lesions. *Sci Signal*. 2017. <https://doi.org/10.1126/scisignal.aai7696>.
19. Wiklander OPB, Bostancioglu RB, Welsh JA, et al. Systematic methodological evaluation of a multiplex bead-based flow cytometry assay for detection of extracellular vesicle surface signatures. *Front Immunol*. 2018;9:1. <https://doi.org/10.3389/fimmu.2018.01326>.
20. Morales-Kastresana A, Musich TA, Welsh JA, et al. High-fidelity detection and sorting of nanoscale vesicles in viral disease and cancer. *J Extracell Vesicles*. 2019;8(1):1597603. <https://doi.org/10.1080/20013078.2019.1597603>.
21. Higginbotham JN, Zhang Q, Jeppesen DK, et al. Identification and characterization of EGF receptor in individual exosomes by fluorescence-activated vesicle sorting. *J Extracell Vesicles*. 2016. <https://doi.org/10.3402/jev.v5.29254>.
22. Welsh JA, Jones JC, Tang VA. Fluorescence and light scatter calibration allow comparisons of small particle data in standard units across different flow cytometry platforms and detector settings. *Cytom Part A*. 2020;97(6):592–601. <https://doi.org/10.1002/cyto.a.24029>.
23. Avci O, Ünlü NL, Özkumur AY, Ünlü MS. Interferometric reflectance imaging sensor (IRIS)—a platform technology for multiplexed diagnostics and digital detection. *Sensors (Switzerland)*. 2015;15(7):17649–65. <https://doi.org/10.3390/s150717649>.
24. Daaboul GG, Gagni P, Benussi L, et al. Digital detection of exosomes by interferometric imaging. *Sci Rep*. 2016;6(1):1–10. <https://doi.org/10.1038/srep37246>.
25. Carney RP, Hazari S, Colquhoun M, et al. Multispectral optical tweezers for biochemical fingerprinting of CD9-positive exosome subpopulations. *Anal Chem*. 2017;89(10):5357–63. <https://doi.org/10.1021/acs.analchem.7b00017>.
26. Royo F, Théry C, Falcón-Pérez JM, Nieuwland R, Witwer KW. Methods for separation and characterization of extracellular vesicles: results of a worldwide survey performed by the ISEV rigor and standardization subcommittee. *Cells*. 2020. <https://doi.org/10.3390/cells9091955>.
27. Guerreiro EM, Vestad B, Steffensen LA, et al. Efficient extracellular vesicle isolation by combining cell media modifications, ultrafiltration, and size-exclusion chromatography. *PLoS ONE*. 2018. <https://doi.org/10.1371/journal.pone.0204276>.
28. Mitchell JP, Court J, Mason MD, Tabi Z, Clayton A. Increased exosome production from tumour cell cultures using the Integra CELLine Culture System. *J Immunol Methods*. 2008;335(1–2):98–105. <https://doi.org/10.1016/j.jim.2008.03.001>.
29. Théry C, Boussac M, Véron P, et al. Proteomic analysis of dendritic cell-derived exosomes: a secreted subcellular compartment distinct from apoptotic vesicles. *J Immunol*. 2001;166(12):7309–18. <https://doi.org/10.4049/jimmunol.166.12.7309>.
30. Hong CS, Muller L, Boyiadzis M, Whiteside TL. Isolation and characterization of CD34+ blast-derived exosomes in acute myeloid leukemia. *PLoS ONE*. 2014. <https://doi.org/10.1371/journal.pone.0103310>.
31. Watson DC, Bayik D, Srivatsan A, et al. Efficient production and enhanced tumor delivery of engineered extracellular vesicles. *Biomaterials*. 2016;105:195–205. <https://doi.org/10.1016/j.biomaterials.2016.07.003>.
32. Gámez-Valero A, Monguió-Tortajada M, Carreras-Planella L, Franquesa M, Beyer K, Borràs FE. Size-Exclusion Chromatography-based isolation minimally alters Extracellular Vesicles' characteristics compared to precipitating agents. *Sci Rep*. 2016;6(1):33641. <https://doi.org/10.1038/srep33641>.
33. Tang Y-T, Huang Y-Y, Zheng L, et al. Comparison of isolation methods of exosomes and exosomal RNA from cell culture medium and serum. *Int J Mol Med*. 2017;40(3):834–44. <https://doi.org/10.3892/ijmm.2017.3080>.
34. Matei AC, Antounians L, Zani A. Extracellular vesicles as a potential therapy for neonatal conditions: state of the art and challenges in clinical translation. *Pharmaceutics*. 2019. <https://doi.org/10.3390/pharmaceutics11080404>.
35. Clark K, Zhang S, Barthe S, et al. Placental mesenchymal stem cell-derived extracellular vesicles promote myelin regeneration in an animal model of multiple sclerosis. *Cells*. 2019. <https://doi.org/10.3390/cells8121497>.
36. Kumar P, Becker JC, Gao K, et al. Neuroprotective effect of placenta-derived mesenchymal stromal cells: role of exosomes. *FASEB J*. 2019;33(5):5836–49. <https://doi.org/10.1096/fj.201800972R>.
37. Welsh JA, Jones JC. Small particle fluorescence and light scatter calibration using FCM PASS software. *Curr Protoc Cytom*. 2020. <https://doi.org/10.1002/cpcy.79>.
38. Welsh JA, Van Der Pol E, Arkesteijn GJA, et al. MIFlowCyt-EV: a framework for standardized reporting of extracellular vesicle flow cytometry experiments. *J Extracell Vesicles*. 2020. <https://doi.org/10.1080/20013078.2020.1713526>.
39. Van der Pol E, Van Gemert MJC, Sturk A, Nieuwland R, Van Leeuwen TG. Single vs swarm detection of microparticles and exosomes by flow cytometry. *J Thromb Haemost*. 2012;10(5):919–30. <https://doi.org/10.1111/j.1538-7836.2012.04683.x>.
40. Lee K, Fraser K, Ghaddar B, et al. Multiplexed profiling of single extracellular vesicles. *ACS Nano*. 2018;12(1):494–503. <https://doi.org/10.1021/acsnano.7b07060>.
41. Kleinmanns K, Fosse V, Bjørge L, McCormack E. The emerging role of cd24 in cancer theranostics—a novel target for fluorescence image-guided surgery in ovarian cancer and beyond. *J Pers Med*. 2020;10(4):1–18. <https://doi.org/10.3390/jpm10040255>.
42. Zhang P, Zhou X, Zeng Y. Multiplexed immunophenotyping of circulating exosomes on nano-engineered ExoProfile chip towards early diagnosis of cancer. *Chem Sci*. 2019;10(21):5495–504. <https://doi.org/10.1039/c9sc00961b>.
43. Im H, Shao H, Park Y II, et al. Label-free detection and molecular profiling of exosomes with a nano-plasmonic sensor. *Nat Biotechnol*. 2014;32(5):490–495. <https://doi.org/10.1038/nbt.2886>.
44. Yoshioka Y, Konishi Y, Kosaka N, Katsuda T, Kato T, Ochiya T. Comparative marker analysis of extracellular vesicles in different human cancer types. *J Extracell Vesicles*. 2013. <https://doi.org/10.3402/jev.v2i0.20424>.
45. Stassen FRM, van Eijck PH, Savelkoul PHM, et al. Cell type- and exposure-specific modulation of CD63/CD81-positive and tissue factor-positive

- extracellular vesicle release in response to respiratory toxicants. *Oxid Med Cell Longev*. 2019;2019:5204218. <https://doi.org/10.1155/2019/5204218>.
46. Moss EL, Hollingworth J, Reynolds TM. The role of CA125 in clinical practice. *J Clin Pathol*. 2005;58(3):308–12. <https://doi.org/10.1136/jcp.2004.018077>.
47. Yoshioka Y, Kosaka N, Konishi Y, et al. Ultra-sensitive liquid biopsy of circulating extracellular vesicles using ExoScreen. *Nat Commun*. 2014;5(1):3591. <https://doi.org/10.1038/ncomms4591>.
48. Zhao Z, Yang Y, Zeng Y, He M. A microfluidic ExoSearch chip for multiplexed exosome detection towards blood-based ovarian cancer diagnosis. *Lab Chip*. 2016;16(3):489–96. <https://doi.org/10.1039/c5lc01117e>.
49. Logozzi M, Angelini DF, Giuliani A, et al. Increased plasmatic levels of psa-expressing exosomes distinguish prostate cancer patients from benign prostatic hyperplasia: a prospective study. *Cancers (Basel)*. 2019. <https://doi.org/10.3390/cancers11101449>.
50. Davies RT, Kim J, Jang SC, Choi E-J, Gho YS, Park J. Microfluidic filtration system to isolate extracellular vesicles from blood. *Lab Chip*. 2012;12(24):5202–5210. <https://doi.org/10.1039/C2LC41006K>.
51. Liang L-G, Kong M-Q, Zhou S, et al. An integrated double-filtration microfluidic device for isolation, enrichment and quantification of urinary extracellular vesicles for detection of bladder cancer. *Sci Reports* 2017 71. 2017;7(1):1.10. <https://doi.org/10.1038/srep46224>.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

